摘要:
The invention relates to the use of at least one compound selected from [[(4-methoxyphenoxy)carbonyl] [4-[2-(5-methyl-2-phenyloxazol-4- yl)ethoxy]benzyl]amino]acetic acid (muraglitazar) and the pharmaceutically acceptable salts thereof, for preparing a pharmaceutical composition for the treatment of skin disorders.
摘要:
The invention relates to novel biaromatic compounds that correspond to the general formula (I) below: and to a method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or alternatively in cosmetic compositions.
摘要:
The invention relates to novel biaromatic compounds which correspond to the general formula (I), and also to a process for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or alternatively in cosmetic compositions.
摘要:
The invention relates to an in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, comprising the determination of the ability of a compound to modulate the expression or the activity of the carboxylesterase 1 (CES1) and/or carboxylesterase 3 (CES3) proteins.
摘要:
L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de ELOVL5 ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
摘要:
The invention relates to the use of at least one activator of PPAR-type receptors in a cosmetic composition or for the preparation of a pharmaceutical composition, said PPAR-type receptor activator or said composition being intended to regulate the size of the sebaceous glands and, in particular, to inhibit sebum production. More specifically, the invention relates to the use of such PPAR activators for the preparation of pharmaceutical compositions that are intended for the treatment of pathologies linked to sebum overproduction or in cosmetic compositions that are intended for the treatment of oily skin and/or a dandruff prone scalp.
摘要:
The invention relates to novel biaromatic compounds that correspond to the general formula (I) below: and to a method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or alternatively in cosmetic compositions.
摘要:
The invention relates to novel biaromatic compounds which correspond to the general formula (I), and also to a process for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or alternatively in cosmetic compositions.
摘要:
The invention relates to markers for rosacea among the chemokines and cytokines and their receptors, chosen from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor, and also to a method for the diagnosis of rosacea.
摘要:
The invention relates to an in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, comprising the determination of the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins.